• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Atara Biotherap (NQ: ATRA )

    0.7186 +0.0212 (+3.04%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 833,904
    Open 0.6884
    Bid (Size) 0.7000 (2)
    Ask (Size) 0.7294 (30)
    Prev. Close 0.6974
    Today's Range 0.6664 - 0.7243
    52wk Range 0.1986 - 3.015
    Shares Outstanding 101,102,152
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Atara Biotherapeutics, Inc.
    Via Business Wire

    Performance

    YTD
    +49.74%
    +49.74%
    1 Month
    +7.27%
    +7.27%
    3 Month
    +19.57%
    +19.57%
    6 Month
    -45.97%
    -45.97%
    1 Year
    -75.56%
    -75.56%

    More News

    Read More
    ATRA Stock Earnings: Atara Biotherapeutics Misses EPS, Misses Revenue for Q4 2023
    Via InvestorPlace
    Atara Biotherapeutics: Q4 Earnings Insights
    Via Benzinga
    Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Why 4D Molecular Therapeutics Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Atara Biotherapeutics Announces $15 Million Registered Direct Offering
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Why Rocket Lab Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.